Savient Pharmaceuticals Jumps On FDA's Approval Of Its Gout Drug

Shares of Savient Pharmaceuticals Inc SVNT surged in pre-market trading after the approval of its gout drug by the Food and Drug Administration (FDA). SVNT's shares surged 23.31% to $18.20 in pre-market trading. The FDA has approved SVNT's gout drug for adults who were not getting any results from conventional therapy. Savient Pharmaceuticals' shares have gained 2.79% over the past month and have risen 8.45% so far this year. Read more from Benzinga's Company news. The $2.5 Million Market-Beating Secret is Available. Get it here for free.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMovers & ShakersFDAMarketsTrading IdeasFood and Drug Administration
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!